Rick A Bright

Summary

Publications

  1. ncbi Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle
    Rick A Bright
    Novavax, Inc, Rockville, Maryland, USA
    PLoS ONE 3:e1501. 2008
  2. ncbi Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin
    Rick A Bright
    Novavax, Inc, Rockville, MD 20850, USA
    Vaccine 25:3871-8. 2007
  3. ncbi H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses
    Kutubuddin Mahmood
    Novavax, Inc, Rockville, MD, USA
    Vaccine 26:5393-9. 2008
  4. ncbi Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza
    Peter Pushko
    Novavax Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 25:4283-90. 2007
  5. ncbi Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
    Mary A Hoelscher
    Influenza Branch, Division of Rickettsial and Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 367:475-81. 2006
  6. ncbi Transmission of equine influenza virus to dogs
    P C Crawford
    College of Veterinary Medicine, University of Florida, Gainesville, FL 32611, USA
    Science 310:482-5. 2005
  7. ncbi Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice
    Hualan Chen
    Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road, N E, MS G16, Atlanta, GA 30333, USA
    Virus Res 128:159-63. 2007
  8. ncbi Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine
    Rick A Bright
    Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Virology 308:270-8. 2003
  9. ncbi Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins
    Judy A Mitchell
    Department of Microbiology and Immunology, School of Medicine, East Carolina University, Brody Health Sciences Building, Room 5N/96E, 600 Moye Boulevard, Greenville, NC 27858-4354, USA
    Vaccine 21:902-14. 2003
  10. ncbi Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide
    Varough M Deyde
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:249-57. 2007

Collaborators

Detail Information

Publications11

  1. ncbi Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle
    Rick A Bright
    Novavax, Inc, Rockville, Maryland, USA
    PLoS ONE 3:e1501. 2008
    ....
  2. ncbi Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin
    Rick A Bright
    Novavax, Inc, Rockville, MD 20850, USA
    Vaccine 25:3871-8. 2007
    ..Interestingly, VLPs elicited antibodies that recognized a broader panel of antigenically distinct H3N2 viral isolates compared to rHA or WIV in a hemagglutination-inhibition (HAI) assay...
  3. ncbi H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses
    Kutubuddin Mahmood
    Novavax, Inc, Rockville, MD, USA
    Vaccine 26:5393-9. 2008
    ..Exploration of immunologic correlates of protection for H5N1 vaccines beyond HAI and neutralizing antibody responses is warranted...
  4. ncbi Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza
    Peter Pushko
    Novavax Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 25:4283-90. 2007
    ..Positive effect of the adjuvant was also detected using the rH9 vaccine. The results have implications for the development of safe and effective vaccines for avian influenza viruses with pandemic potential...
  5. ncbi Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
    Mary A Hoelscher
    Influenza Branch, Division of Rickettsial and Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 367:475-81. 2006
    ..01). INTERPRETATION: Our findings highlight the potential of an Ad-vector-based delivery system, which is both egg-independent and adjuvant-independent and offers stockpiling options for the development of a pandemic influenza vaccine...
  6. ncbi Transmission of equine influenza virus to dogs
    P C Crawford
    College of Veterinary Medicine, University of Florida, Gainesville, FL 32611, USA
    Science 310:482-5. 2005
    ..Evidence of infection in pet dogs suggests that this infection may also become enzootic in this population...
  7. ncbi Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice
    Hualan Chen
    Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road, N E, MS G16, Atlanta, GA 30333, USA
    Virus Res 128:159-63. 2007
    ..Multiple genes are involved in virulence of Hong Kong H5N1 influenza A viruses for mice with the presence of lysine at aa627 in the PB2 gene exhibiting a significantly larger effect than the HA and NA genes...
  8. ncbi Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine
    Rick A Bright
    Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Virology 308:270-8. 2003
    ....
  9. ncbi Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins
    Judy A Mitchell
    Department of Microbiology and Immunology, School of Medicine, East Carolina University, Brody Health Sciences Building, Room 5N/96E, 600 Moye Boulevard, Greenville, NC 27858-4354, USA
    Vaccine 21:902-14. 2003
    ..The HA-mC3d(3)-DNA vaccinated mice were protected from heterologous influenza challenge, even though sera from these mice had no viral-neutralizing activity against heterologous virus...
  10. ncbi Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide
    Varough M Deyde
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:249-57. 2007
    ..The results of the study highlight the necessity of close monitoring of resistance to existing antivirals as wells as the need for new therapeutics...
  11. ncbi Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008
    Tiffany G Sheu
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 52:3284-92. 2008
    ..6% (50/579 isolates). The recent increase in oseltamivir resistance among A(H1N1) viruses isolated from untreated patients raises public health concerns and necessitates close monitoring of resistance to NA inhibitors...